journal article·2020-10Open access

E3 Ligase FBXW2 Is a New Therapeutic Target in Obesity and Atherosclerosis

Cheng Wang, Wenjing Xu, Yuelin Chao, Minglu Liang, Fengxiao Zhang, Kai Huang

Advanced Science· Volume 7· Issue 20

Abstract

Abstract Chronic low‐grade inflammation orchestrated by macrophages plays a critical role in metabolic chronic diseases, like obesity and atherosclerosis. However, the underlying mechanism remains to be elucidated. Here, the E3 ubiquitin ligase F‐box/WD Repeat‐Containing Protein 2 (FBXW2), the substrate‐binding subunit of E3 ubiquitin ligase SCF (a complex of FBXW2, SKP1, and cullin‐1), as an inflammatory mediator in macrophages, is identified. Myeloid‐specific FBXW2 gene deficiency improves both obesity‐associated with insulin resistance and atherosclerosis in murine models. The beneficial effects by FBXW2 knockout are accompanied by decreased proinflammatory responses and macrophage infiltration in the microenvironment. Mechanistically, it is identified that KH‐type splicing regulatory protein (KSRP) is a new bona fide ubiquitin substrate of SCFFBXW2. Inhibition of KSRP prevents FBXW2‐deficient macrophages from exerting a protective effect on inflammatory reactions, insulin resistance and plaque formation. Furthermore, it is demonstrated that the C‐terminus (P3) of FBXW2 competitively ablates the function of FBXW2 in KSRP degradation and serves as an effective inhibitor of obesity and atherogenesis progression. Thus, the data strongly suggest that SCFFBXW2 is an important mediator in the context of metabolic diseases. The development of FBXW2 (P3)‐mimicking inhibitors and small‐molecular drugs specifically abrogating KSRP ubiquitination‐dependent inflammatory responses are viable approaches for obesity and atherosclerosis treatment.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Ubiquitin and proteasome pathways · Cancer-related gene regulation · RNA modifications and cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Clinic Center of Human Gene Research Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430022 China

Department of Rheumatology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430022 China

Department of Cardiology Nanjing First Hospital Nanjing Medical University Nanjing 210029 China

Funding

National Natural Science Foundation of China

References (39)

Show source-provided references
1. 10.3390/ijms1504618410.3390/ijms15046184 ↗
2. 10.1253/circj.CJ-11-118410.1253/circj.CJ-11-1184 ↗
3. Lopez‐Candales A. · J. Nat. Sci. · 2017 · 3
4. 10.3389/fimmu.2014.0049110.3389/fimmu.2014.00491 ↗
5. 10.1159/00029650710.1159/000296507 ↗
6. 10.1016/j.bbamcr.2014.05.01410.1016/j.bbamcr.2014.05.014 ↗
7. 10.3389/fphys.2014.0014610.3389/fphys.2014.00146 ↗
8. 10.1186/s12944-015-0123-110.1186/s12944-015-0123-1 ↗
9. 10.1016/j.febslet.2007.11.05710.1016/j.febslet.2007.11.057 ↗
10. 10.1111/joim.1240610.1111/joim.12406 ↗
11. 10.7150/thno.4273510.7150/thno.42735 ↗
12. 10.1038/ncomms1400210.1038/ncomms14002 ↗
13. 10.1038/s41467-019-09289-510.1038/s41467-019-09289-5 ↗
14. 10.1016/j.heliyon.2018.e0078210.1016/j.heliyon.2018.e00782 ↗
15. 10.1095/biolreprod.108.07140710.1095/biolreprod.108.071407 ↗
16. 10.1146/annurev.immunol.021908.13262010.1146/annurev.immunol.021908.132620 ↗
17. 10.1042/BJ2005183910.1042/BJ20051839 ↗
18. 10.1172/JCI8442610.1172/JCI84426 ↗
19. 10.1002/cbin.1080410.1002/cbin.10804 ↗
20. 10.1096/fj.09-13134210.1096/fj.09-131342 ↗
21. 10.1074/jbc.M41398620010.1074/jbc.M413986200 ↗
22. 10.2174/18715301079121310010.2174/187153010791213100 ↗
23. 10.1210/jc.2004-037210.1210/jc.2004-0372 ↗
24. 10.1161/CIRCRESAHA.116.30759110.1161/CIRCRESAHA.116.307591 ↗
25. 10.3389/fendo.2016.0003010.3389/fendo.2016.00030 ↗
26. 10.1007/s11154-014-9306-810.1007/s11154-014-9306-8 ↗
27. Wilkinson K. D. · Anticancer Drug Des. · 1987 · 2 · 211
28. 10.1073/pnas.190597311610.1073/pnas.1905973116 ↗
29. 10.1093/nar/gkw104210.1093/nar/gkw1042 ↗
30. 10.1016/j.molcel.2004.05.00210.1016/j.molcel.2004.05.002 ↗
31. 10.1002/glia.2239610.1002/glia.22396 ↗
32. 10.1093/nar/gku103310.1093/nar/gku1033 ↗
33. 10.1096/fj.201801267RR10.1096/fj.201801267RR ↗
34. Weischenfeldt J. · CSH Protoc. · 2008 · 3 · pdb prot5080
35. 10.1038/nm.382910.1038/nm.3829 ↗
36. 10.1128/MCB.00160-1310.1128/MCB.00160-13 ↗
37. 10.1038/s41419-018-0875-410.1038/s41419-018-0875-4 ↗
38. 10.1038/s41467-019-09174-110.1038/s41467-019-09174-1 ↗
39. 10.2337/db19-063510.2337/db19-0635 ↗